Table 1.

MRP2 immunoreactivity in patients with renal-cell carcinomaa

PatientStage (TNM)bGrade (G)cHistopathologyMRP2 Expressiond
RCCKidney Cortex
aPatients underwent tumor surgery without preoperative chemotherapy or irradiation treatment. The mean age of all patients undergoing tumor-nephrectomy was 63.5 yr (range, 47 to 89). Immunoblotting was performed with the EAG5 antibody as shown in the examples given in Figures 2 and 3.
bpTNM, postoperative tumor staging (28).
cPathohistologic tumor grading.
dImmunoreactivity for MRP2: +++, strong; ++, positive; +, weak; -, negative.
eNo kidney tissue available because of nephron-sparing surgery.
1pT2N0M1G1Clear-cell++++++
2pT3N0M0G1Clear-cell++++++
3pT2N0M0G1Clear-cell+++++
4pT2N0M0G1Clear-cell+++++
5pT2N0M0G2Clear-cell+++e
6pT2N0M0G1Clear-cell++e
7pT2N0M0G1Clear-cell+++++
8pT2N0M1G2Clear-cell+++++
9pT3N0M0G2Clear-cell+++++
10pT2N0M2G2Clear-cell+++++
11pT3N0M0G2Clear-cell+++++
12pT2N0M0G2Clear-cell+++++
13pT2N0M1G2Clear-cell+++++
14pT2N0M0G2Clear-cell++++
15pT3N2M1G3Clear-cell+++++
16pT2N0M0G3Clear-cell++++
17pT2N0M1G3Clear-cell++++
18pT2N0M0G3Clear-cell++++
19pT4N0M0G3Clear-cell-+++